Medical Instruments & Supplies / Medical Technology
Strategic Profile
Zeiss holds the second-largest market position in ophthalmology with low-teens share of the market, while commanding over 60% market share in the microsurgery space, making it the clear leader. The company operates in two segments: ophthalmic devices and microsurgery. Recent analyst sentiment reflects concerns about slowing growth momentum in FY2025-26.
Cyborg Score Rationale
The company experienced a weak start to FY2025-26 with tough times ahead. Revenue growth is expected to slow substantially to 3.3% in 2026 versus historical 9.3% growth over five years. Strong market positions in microsurgery offset near-term operational headwinds.
Top Insights
Analysts forecast 2026 revenues of €2.30B, representing 3.3% improvement versus last 12 months.
Ophthalmology segment comprises 75% of sales, including refractive lasers, surgical devices, and intraocular lenses.
Analysts downgraded earnings per share estimates following recent results, indicating decline in sentiment.
Carl Zeiss Meditec employs 3,371 people and is traded on Frankfurt Stock Exchange.
Named Competitors
Surgical Robotics & Vision Systems — Robotic surgical systems with extensive ophthalmology applications
Vision Care Products — Integrated vision care and optical solutions
Surgical Visualization & Microscopy — Surgical endoscopy and visualization equipment
Recent Developments
(December 2025) Analysts downgraded 2026 earnings per share forecasts to €1.92, showing sentiment decline post-results
(December 2025) Full-year results revealed weak start to FY2025-26 with challenging outlook ahead
(April 2024) Acquisition of Dutch Ophthalmic Research Center completed
Open the full interactive Carl Zeiss Meditec AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.